ascendis pharma glp-1 Novo puts $285m into monthly based on tech Novo Nordisk and Ascendis enter
Description
Compare Sermorelin and Semaglutide for weight loss

To help ensure an expanded healthy lifespan for as many people as possible worldwide, there is a need to prevent or manage a number of prevalent chronic diseases directly and indirectly closely related to aging, including diabetes and obesity

Learn the safety guidelines, the 48-hour rule, and how to safely adjust your dosing schedule today.

Key highlights: Once-daily oral administration Up to 11.8% weight loss over 36 weeks Focus on broader cardiometabolic health outcomes Advancement into Phase III development As obesity remains one of the most significant global health challenges, innovation in oral GLP-1 therapies could help improve accessibility and patient adherence while expanding treatment options beyond injectable therapies

Weight regain after stopping Ozempic affects up to 70% of patients within one year

Yet what happens after someone starts taking them receives far less attention
